Organon (OGN) Research & Development (2020 - 2026)
Organon (OGN) posted quarterly Research & Development of $90.0 million for Q2 2026, down 5.26% year-over-year from $95.0 million in Q2 2025, and down 3.23% on a QoQ basis from $93.0 million in Q1 2026.
Organon (OGN) Research & Development (2020 - 2026) Analysis & Trends
Organon has reported Research & Development for 7 years, with the latest figure at $90.0 million in Q2 2026.
- Research & Development for Q2 2026 came in at $90.0 million, down 5.26% year-over-year; the trailing twelve-month figure through Jun 2026 was $358.0 million (down 12.9% YoY), and the FY2025 annual result was $366.0 million, down 21.96% from the prior year.
- Research & Development fell to $90.0 million in Q2 2026, from $93.0 million in the prior quarter.
- Over five years, Research & Development peaked at $170.0 million in Q1 2024 and troughed at $84.0 million in Q3 2025.
- A 5-year average of $114.1 million and a median of $111.0 million in 2022 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development jumped 47.67%; it then slumped 43.53% in 2025.
- A 5-year view of Research & Development shows it stood at $142.0 million in 2022, then slipped by 5.63% to $134.0 million in 2023, then dropped by 2.99% to $130.0 million in 2024, then fell by 30.0% to $91.0 million in 2025, then fell by 1.1% to $90.0 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $90.0 million in Q2 2026, $93.0 million in Q1 2026, and $91.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn | 90.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.00 Mn |
| Mar 31, 2026 | 93.00 Mn |
| Dec 31, 2025 | 91.00 Mn |
| Sep 30, 2025 | 84.00 Mn |
| Jun 30, 2025 | 95.00 Mn |
| Mar 31, 2025 | 96.00 Mn |
| Dec 31, 2024 | 130.00 Mn |
| Sep 30, 2024 | 90.00 Mn |
| Jun 30, 2024 | 116.00 Mn |
| Mar 31, 2024 | 170.00 Mn |
| Dec 31, 2023 | 134.00 Mn |
| Sep 30, 2023 | 137.00 Mn |
| Jun 30, 2023 | 128.00 Mn |
| Mar 31, 2023 | 129.00 Mn |
| Dec 31, 2022 | 142.00 Mn |
| Sep 30, 2022 | 127.00 Mn |
| Jun 30, 2022 | 106.00 Mn |
| Mar 31, 2022 | 96.00 Mn |
| Dec 31, 2021 | 110.00 Mn |
| Sep 30, 2021 | 86.00 Mn |